Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Wednesday 15 December, 2021

C4X Discovery

Annual Report and Notice of AGM

RNS Number : 6660V
C4X Discovery Holdings PLC
15 December 2021
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Posting of 2021 Annual Report and Notice of AGM

 

15 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 July 2021 and Notice of the Annual General Meeting ("AGM") which will be held at Panmure Gordon, One New Change, London, EC4M 9AF, on 18 January 2022 at 2.00 p.m. (GMT).

The Annual Report and Accounts and notice of AGM are also available to view on, and download from, the Company's website at www.c4xdiscovery.com  

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFFFFSLSLIL

a d v e r t i s e m e n t